Amide proton transfer imaging reveals cerebral metabolic alterations associated with cognitive impairment in type 2 diabetes mellitus.

ABSTRACT:

Background

Amide proton transfer (APT) imaging indirectly reflects tissue metabolic changes by detecting variations in the concentration of mobile amide protons and tissue pH. Type 2 diabetes mellitus (T2DM) is often accompanied by cognitive dysfunction and diabetic encephalopathy, both of which pose serious threat to human health and quality of life. This study aimed to evaluate the potential of APT imaging as a novel biomarker for detecting cerebral metabolic alterations and to investigate its associations with cognitive impairment in patients with T2DM.

Methods

This study included 32 T2DM patients, comprising 16 with mild cognitive impairment (MCI) and 16 with normal cognition (NC), and 26 healthy controls. Clinical data and cognitive assessments were collected within one

SUBMITTER: Jiang H 

PROVIDER: S-EPMC12502362 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature